Business

Cardio Diagnostics Named to Fast Company’s Second Annual List of the Next Big Things in Tech

List Recognizes Tech Breakthroughs Across Industries That Promise to Transform the Future CHICAGO--(BUSINESS WIRE)-- Cardio Diagnostics (Nasdaq: CDIO), a

articleCardio Diagnostics Holdings Inc.November 17, 20224/company/cardio-diagnostics-holdings-inc/news/cardio-diagnostics-named-to-fast-companys-second-annual-list-of-the-next-big-things-in-tech
Cardio Diagnostics Named to Fast Company’s Second Annual List of the Next Big Things in Tech

About this update from Cardio Diagnostics Holdings Inc.

[{"type":"text","content":"\nList Recognizes Tech Breakthroughs Across Industries That Promise to Transform the Future\n\n CHICAGO--(BUSINESS WIRE)--\nCardio Diagnostics (Nasdaq: CDIO), a precision cardiovascular disease company, today announced that it has been named to Fast Company’s second annual Next Big Things in Tech list, honoring technology breakthroughs that promise to shape the future of industries—from agriculture and environment to productivity and artificial intelligence.\n\nThis year, 83 technologies developed by established companies, startups or research teams are highlighted for their cutting-edge advancements and potential to impact consumers, businesses and society overall. While not all of the technological developments are available in the market yet, each one is reaching key milestones in order to have a proven impact in the next five years. Fast Company also recognized 41 honorable mentions.\n\nCardio Diagnostics is a biotechnology company that makes cardiovascular disease prevention and early detection more accessible, personalized, and precise. The company’s scientific and clinical studies have shown that an approach, which combines the emerging science of epigenetics and genetics, high-throughput computing, and AI, can close the current gap in our ability to clinically and precisely identify those at risk for heart disease.\n\n“AI is playing an increasingly important role in healthcare, as it can be used to help identify and treat diseases,” said CTO Tim Dogan, PhD. “We are so honored at Cardio Diagnostics to have our heart disease solutions at the intersection of high-performance computing, machine learning, and integrated epigenetics-genetics recognized.”\n\n“Technology breakthroughs and cutting-edge advancements promise to be the solution to some of the world’s most pressing issues. Fast Company is excited to highlight some of the organizations, of all sizes and industry backgrounds, whose technology advancements today will lead to a better tomorrow,” says Brendan Vaughan, editor-in-chief of Fast Company.\n\nClick here to see the final list.\n\nThe Winter 2022/2023 issue of Fast Company is available online now and will hit newsstands on December 6.\n\nAbout Fast Company\n\nFast Company is the only media brand fully dedicated to the vital intersection of business, innovation, and design, engaging the most influential leaders, c...

More updates from Cardio Diagnostics Holdings Inc.